Gastroenterology

Transforming Anti-HCV Treatment:
The Potential for Specifically Targeted
Antiviral Therapy for HCV (STAT-C)

This CME activity has reached its termination date and no longer offers continuing education credit. Please note that expired CME activities may not contain the most up-to-date information available.

Click here to view our current activities in Gastroenterology.

You may also be interested in Advanced Certificate Program III: Bridging Cultural Differences to Improve HBV Treatment in Asian and Other Diverse Communities

Transforming Anti-HCV Treatment: The Potential for Specifically Targeted Antiviral Therapy for HCV (STAT-C)

Dear Colleague,

The development of specifically targeted drugs, such as VX-950, SCH 503034, and NM-283, represents the beginning of a new era in anti-HCV therapy. Although the immunomodulatory effect of peginterferon plus ribavirin has produced sustained virologic response in a significant proportion of HCV-infected patients, new therapies that target key points in HCV viral kinetics offer exciting possibilities for more effective combination therapies. For example, direct antivirals may enhance the action of interferon, thus reducing the duration of peginterferon-based therapy. In addition, these targeted agents offer the potential for individualized therapy according to patient-specific factors. HCV-infected patients, including those who are difficult to treat—patients infected with genotype 1, patients at risk of anemia, prior nonresponders, and patients coinfected with HIV—will find new options for enhanced response to treatment.

Transforming Anti-HCV Treatment: The Potential for Specifically Targeted Antiviral Therapy for HCV (STAT-C) brings you the audio presentations from the satellite symposium held at the 12^th International Symposium on Viral Hepatitis and Liver Disease (ISVHLD) on July 2, 2006, in Paris. In this free online CME activity, which includes downloadable slides and syllabus, our expert faculty provides the latest safety, efficacy, and resistance data of VX-950, SCH 503034, and NM-283, and also discusses how these new agents will change our current therapeutic strategies. You can also order a free CD-ROM version of this activity containing the audio presentations, slides, and syllabus.

This program offers an exciting preview of a new era of anti-HCV treatment using potent targeted agents. Take advantage of this important and informative educational opportunity today!

Sincerely,

CHAIR
Alfredo Alberti, MD Professor of Internal Medicine and Gastroenterology University of Padova Padova, Italy

FACULTY
Yves Benhamou, MD Praticien Hospitalier Service d'Hepato-Gastro-Enterologie Groupe Hospitalier Pitie-Salpetriere Paris, France	Stefan Zeuzem, MD Professor of Medicine Department of Internal Medicine II Gastroenterology, Hepatology, and Endocrinology University Hospital Homburg/Saar, Germany
John G. McHutchison, MD, FRACP Professor of Medicine Director, Gastroenterology/ Hepatology Research Duke University Medical Center Durham, North Carolina

top

TARGET AUDIENCE

This CME activity is designed for gastroenterologists, hepatologists, and other clinicians who treat patients with HCV infection.

ACTIVITY GOAL

The goal of this activity is to provide state-of-the-art, clinically relevant information that will provide clinicians with new insights into HCV, molecular approaches to anti-HCV therapy, pipeline protease and polymerase inhibitors, and enable them to identify the potential role that these agents may play in the future.

LEARNING OBJECTIVES

Integrate knowledge of molecular interactions with HCV at the cellular level and mechanism of action of protease and polymerase inhibitors to determine the potential role of these therapies in producing virologic and histologic response in HCV-infected patients.
Relate viral kinetics to patient outcomes in evaluating virologic and histologic response to therapy in HCV-infected patients.
Differentiate potential efficacy and safety considerations of protease and polymerase inhibitors, based on efficacy and safety data from early clinical trials, as therapeutic options in the future treatment of patients with HCV infection.
Based on preliminary data, assess the potential for therapeutic strategies involving protease and polymerase inhibitors to improve virologic and histologic response in HCV-infected patients.

top

CME INFORMATION

Statement of Accreditation

Projects In Knowledge is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Projects In Knowledge designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

This activity is planned and implemented as an independent CME activity in accordance with the ACCME Essential Areas and Policies.

Contract for Mutual Responsibility in CME/CE
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.

top

DISCLOSURE INFORMATION

The Disclosure Policy of Projects In Knowledge requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.

For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians' Desk Reference (PDR).

Alfredo Alberti, MD, has received grant/research support from Roche Pharmaceuticals and Schering-Plough Corporation; is a consultant for Gilead Sciences, Inc, Idenix Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Roche Pharmaceuticals, Schering-Plough Corporation, and Vertex Pharmaceuticals Incorporated; and is on the speakers bureau of Roche Pharmaceuticals and Schering-Plough Corporation. Dr. Alberti has disclosed that he will reference unlabeled/unapproved uses of BILN 2061, SCH 503034, and VX-950.

Yves Benhamou, MD, has received grant/research support from Abbott Laboratories, Gilead Sciences, Inc, Roche Pharmaceuticals, and Schering-Plough Corporation; is a consultant for Abbott Laboratories, Boehringer Ingelheim Pharmaceuticals, Inc, Human Genome Sciences, Idenix Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Roche Pharmaceuticals, Schering-Plough Corporation, Valeant Pharmaceuticals International, and Vertex Pharmaceuticals Incorporated; and is on the speakers bureau of Abbott Laboratories, Boehringer Ingelheim Pharmaceuticals, Inc, GlaxoSmithKline, Human Genome Sciences, Idenix Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Roche Pharmaceuticals, Schering-Plough Corporation, and Valeant Pharmaceuticals International. Dr. Benhamou has disclosed that he will reference unlabeled/unapproved uses of NM-283, R1626, SCH 503034, and VX-950.

John G. McHutchison, MD, FRACP, has received grant/research support from Coley Pharmaceutical Group, First Circle Medical, Inc, GlaxoSmithKline, Human Genome Sciences, Idenix Pharmaceuticals Inc, InterMune Inc, Roche Pharmaceuticals, Schering-Plough Corporation, SciClone Pharmaceuticals, Valeant Pharmaceuticals International, and Vertex Pharmaceuticals Incorporated; and is a consultant for or on the speakers bureau of Anadys Pharmaceuticals, Inc, Aus Bio PTL, Coley Pharmaceutical Group, First Circle Medical, Inc, GlaxoSmithKline, Human Genome Sciences, Idenix Pharmaceuticals Inc, National Genetics Institute, Novartis Pharmaceuticals Corporation, Nucleonics, Inc, Otsuka America Pharmaceutical, Inc, Peregrine Pharmaceuticals, Inc, Roche Pharmaceuticals, Schering-Plough Corporation, SciClone Pharmaceuticals, United Therapeutics, Valeant Pharmaceuticals International, Vertex Pharmaceuticals Incorporated, and XTL. Dr. McHutchison has disclosed that he will reference unlabeled/unapproved uses of NM-283, SCH 503034, and VX-950.

Stefan Zeuzem, MD, has received grant/research support from, is a consultant for, and is on the speakers bureau of Gilead Sciences, Inc, Idenix Pharmaceuticals Inc, InterMune Inc, Roche Pharmaceuticals, Schering-Plough Corporation, Novartis Pharmaceuticals Corporation, Valeant Pharmaceuticals International, and Vertex Pharmaceuticals Incorporated. Dr. Zeuzem has disclosed that he will reference unlabeled/unapproved uses of NM-283, SCH 503034, and VX-950.

Peer Reviewer has disclosed no significant relationships.

Projects In Knowledge's staff members have no significant relationships to disclose.

Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.

The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.

This CME activity is provided by Projects In Knowledge solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.

This independent CME activity is supported by an educational grant from
Vertex Pharmaceuticals Incorporated.

top

1776